CD22 CAR-T

DRUG5 trials

Sponsors

Kai Lin Xu; Jun Nian Zheng, Hebei Senlang Biotechnology Inc., Ltd.

Conditions

Adult B Acute Lymphoblastic LeukemiaB-ALLChildhood Acute Lymphoblastic LeukemiaRecurrent or Refractory B Cell MalignancyRefractory Indolent Adult Non-Hodgkin Lymphoma

Early Phase 1

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Hebei Senlang Biotechnology Inc., Ltd.Refractory Indolent Adult Non-Hodgkin Lymphoma

Start: 2020-04-01End: 2023-03-30Target: 100Updated: 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.Childhood Acute Lymphoblastic Leukemia

Start: 2020-04-01End: 2023-05-30Target: 50Updated: 2020-11-13

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Hebei Senlang Biotechnology Inc., Ltd.Adult B Acute Lymphoblastic Leukemia

Start: 2020-04-01End: 2023-05-30Target: 50Updated: 2020-11-13

Phase 1

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Kai Lin Xu; Jun Nian ZhengRecurrent or Refractory B Cell Malignancy

Start: 2016-06-30End: 2019-06-30Target: 10Updated: 2016-06-09

Unknown Phase

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.B-ALL

Start: 2020-09-01End: 2022-12-01Target: 20Updated: 2020-09-14

Related Papers

Safety and Efficacy of CD 19 CAR T Cells (S1904) in Patients with RR B-ALL: A Pooled Analysis of Two Early-Phase Trials

Blood2024-11-05